Theranostics Health, Inc. and its collaborators are presenting results on the use of the TheraLink® Assay to assess drug target and pathway activation to predict drug response and resistance in key breast cancer clinical populations.
To read more: Theranostics_Announcement_2015 ASCO Posters
Theranostics Health announced today that it has been awarded accreditation by the College of American Pathologists (CAP) for its high complexity CLIA laboratory that offers the TheraLink® Assay for Breast Cancer, a comprehensive phospho-proteomic molecular test employing reverse-phase protein array technology to help oncologists make more informed treatment decisions for patients with cancer.
To read the press release: Theranostics Health_CAP-CLIA Accreditation
2:50 pm, Tuesday May 5, 2015
Loews Philadelphia Hotel
Glenn Hoke, Ph.D., Executive Vice President and COO, is providing a presentation on the TheraLink®Assay for Breast Cancer titled “A novel Phospho-Proteomic Diagnostic for Patient Stratification and Therapy Selection for Breast Cancer” at the Biomarker World Congress.
Theranostics Health, Inc., announced today a series of agreements to expand on current research and commercial collaborations with Avera Health to assess the TheraLink® Assay technologies as a proteomic-based personalized medicine tool in breast cancer, and to help explore its potential utility in a number of other key cancers.
To read more: Avera Health TheraLink® Technology Collaboration
Theranostics Health, Inc., announced today the launch of a greatly enhanced TheraLink® Assay Panel for Breast Cancer that incorporates several improvements in its ability to identify the best therapeutic choices for treating patients with advanced, refractory, or inflammatory breast cancer.
To read more: TheraLink® Assay Expansion for Breast Cancer
Theranostics Health Inc. announces today a joint publication with the Georgetown Lombardi Cancer Center in the American Cancer Society’s journal Cancer of “A Phase 1 Study of Cetuximab and Lapatinib in Patients with Advanced Solid Tumor Malignancies” that supports the use of measuring drug target up-regulation and activation to predict response to therapy.
Cancer Journal Deeken et al
Theranostics Health welcomes the appointment of five preeminent medical researchers to its Medical Advisory Board (MAB).
- Brian Leyland-Jones, MD serves as Vice President of Molecular and Experimental Medicine with Avera Medical Group. Dr. Leyland-Jones will Chair the MAB.
- Massimo Cristofanilli, MD serves as Director of the Jefferson Breast Care Center at the Kimmel Cancer Center and Thomas Jefferson University and Hospital.
- Lance Liotta, MD, PhD serves as University Professor and Co-Director Center for Applied Proteomics and Molecular Medicine at George Mason University.
- Joyce O’Shaughnessy, MD serves as Co-Chair of Breast Cancer Research at Baylor-Sammons Cancer Center and for the US Oncology Network.
- Neil L. Spector, MD, serves as Associate Professor of Medicine, Pharmacology & Cancer Biology at the Duke University School of Medicine.
Theranostics Health_MAB PR_Feb 6, 2015
Luis Gutierrez, President and CEO, will be presenting at the Biotech Showcase™ 2015 Conference being held in San Francisco, CA on Monday, January 12.
Biotech Showcase 2015 – Theranostics Health
Theranostics Health, Inc., a biotechnology company that develops and commercializes molecular diagnostic technologies to target therapies for optimal patient benefit, announced today the appointment of Luis T. Gutierrez, Jr. as President and Chief Executive Officer. In that role, he will also join the company’s Board of Directors. Glenn D. Hoke, PhD will remain with the company in the role of Executive Vice President and Chief Operating Officer.
TH Luis Gutierrez Press Release 10.27.2014
Theranostics Health, Inc. and Grace Bio-Labs of have entered into a Product Licensing Agreement for the manufacture and market distribution of Theranostic’s novel tissue preservative, TheraLin®. Under the terms of the agreement, Grace Bio-Labs will be the commercial manufacturer and distributor for the patented (US Patent 8,460,859) TheraLin® fixative with the objective of accelerating the utilization of this novel reagent for advancement of cellular and protein analysis.
Theranostics_Grace_TheraLin Press Release
Select here for product and ordering information on the TheraLin® Tissue Fixative